Russell Investments Group
STLN

Russell Investments Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Russell Investments Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
20,260
+15,268
+306% +$64.1K ﹤0.01% 3420
2026
Q1 		$15.3K Buy
4,992
+61
+1% +$187 ﹤0.01% 3689
2025
Q4 		$17.6K Buy
4,931
+42
+0.9% +$156 ﹤0.01% 3658
2025
Q3 		$17.1K Buy
+4,889
New +$16.8K ﹤0.01% 3633

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

Russell Investments Group's STLN Position: Q2 2026 in Review

Russell Investments Group increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 306% in Q2 2026, buying an estimated $64.1K and bringing the position to 20,260 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

Russell Investments Group first reported a position in STLN in Q3 2025 and has held it in 4 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Russell Investments Group held 20,260 shares of Starling Oncology Institute, Inc. Common Stock worth $110K as of Q2 2026.
  • Russell Investments Group bought 15,268 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $64.1K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3420 holding.
  • Russell Investments Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 4 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.